A novel murine model of allogeneic vaccination against renal cancer.
OBJECTIVE
To develop a murine model for whole-cell allogeneic vaccination in renal cancer, as such vaccines aim to direct immune responses against patient tumour cells, due to shared antigens between the vaccine and tumour cells.


METHODS
A novel murine renal cell line, allogeneic to BALB/c, was developed from a C57BL/6 mouse by primary cell culture (RVIK). It was immortalized by HPV16 E6/E7 and transfected with ras in an attempt to improve its immunogenicity. The cell line was characterized and tested as a vaccine in a BALB/c tumour-protection model after subsequent tumour challenge with autologous RenCa tumour cells.


RESULTS
RVIK alone, with no ras induced cross-reactive immunity, providing a valid non-tumorigenic allogeneic whole-cell vaccine model for renal cancer. Ras transfection per se did not improve RVIK immunity.


CONCLUSIONS
RVIK is a novel immunogenic murine renal epithelial cell line, which confers protection when used as an allogeneic vaccine. It provides proof of principle for the effectiveness of allogeneic whole-cell vaccines and may therefore form the basis of a useful model of allogeneic vaccination to further optimize vaccination schedules, formulation and adjuvants for a clinical setting.
Havranek
Erik G
EG
Department of Urology, St. George's Hospital, London, UK.
Labarthe
Marie-Christine
MC
Ward
Stephen
S
Anderson
Christopher J
CJ
Whelan
Michael A
MA
Pandha
Hardev
H
D000818:Animals; D019496:Cancer Vaccines; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000517:prevention & control*; D002455:Cell Division; D007680:Kidney Neoplasms / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D023421:Models, Animal; D016019:Survival Analysis; D014407:Tumor Cells, Cultured
D019496:Cancer Vaccines